Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049870 | 0.82 | NPY1R (0.31) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL2230914 | 0.80 | NPY1R (0.32) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL12265102 | 0.78 | KDM4E (0.36) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL12312734 | 0.78 | KDM4E (0.36) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22172267 | 0.78 | KDM4E (0.36) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL12539661 | 0.78 | KDM4E (0.36) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22172259 | 0.78 | KDM4E (0.36) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL20995896 | 0.76 | — | — | |
| SCHEMBL11930083 | 0.75 | CA1 (0.36) | — | |
| SCHEMBL9224806 | 0.73 | NPY1R (0.33) | NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736968-B2 | Cellular signalling inhibitors, their formulations and methods thereof | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2020-08-11 | — | — | US | disclosed |
| US-20190046650-A1 | CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2019-02-14 | — | — | US | disclosed |
| EP-2469338-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION FOR LITHOGRAPHY CONTAINING RESIN HAVING ALIPHATIC RING AND AROMATIC RING | Nissan Chemical Industries, Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736968-B2 | Cellular signalling inhibitors, their formulations and methods thereof | CSF1R, CSF3R, MSR1 | NPY1R 1904/4885NPY2R 2768/4885NPY4R 3672/4885 |
| US-20190046650-A1 | CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF | CSF1R, CSF3R, MSR1 | NPY1R 2058/4885NPY2R 2931/4885NPY4R 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.